Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04879407 · ClinicalTrials.gov registry record

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

A clinical trial of Pulmonary Embolism, sponsored by Brigham and Women's Hospital.

Completed
Registry status
98,947
Enrollment target
1
Study location

NCT04879407 is a study of Pulmonary Embolism that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 98,947 participants, above the 997-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (9824% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04879407, a study of Pulmonary Embolism, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
98,947 participants
Enrollment target
1
Study location

Study Summary

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Conditions Studied

Interventions

  • DRUG Warfarin
  • DRUG Rivaroxaban

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 98,947 participants
Start Date 2020-10-10
Est. Completion 2021-06-11

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04879407

The ClinicalTrials.gov registry entry for NCT04879407 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98,947 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 997-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (9824% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Warfarin is the first listed.

NCT04879407 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04879407 about?

NCT04879407 is a clinical study titled "Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...

What is the current status of trial NCT04879407?

This trial is currently completed. The enrollment target is 98,947 participants. The study started on 2020-10-10. Estimated completion is 2021-06-11.

What conditions does trial NCT04879407 study?

This clinical trial studies the following conditions: Pulmonary Embolism.

What interventions are being tested in trial NCT04879407?

The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (DRUG).

Who is sponsoring clinical trial NCT04879407?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04879407 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Embolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.